600380.SS
600380.SS
CNE000001816
JOINCARE PHARMACEUTICAL GROUP I
Loading chart...

Company Profile

Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products in China and internationally. The company offers chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection; chemical APIs and intermediates for drugs for humans and veterinary drugs; and traditional Chinese medicine, including cold medicine anti-viral granules and anti-tumor medicine. It also provides diagnostic reagents and equipment, such as mycoplasma pneumoniae IgM antibody test and antinuclear antibody test kit; OTC products which includes Taitai and Jingxin oral liquid, Eagle's American ginseng tea, and YikeTie; and biologics comprising tocilizumab and mouse nerve growth factor injection. The company was founded in 1992 and is headquartered in Shenzhen, China.

Related stocks

600664.SS
600664.SS • China
HARBIN PHARMACEUTICAL GROUP CO
7.39 CNY
2.78B USD 1Y +105.3%
1513.HK
1513.HK • China
LIVZON PHARMA
22.16 HKD
2.51B USD 1Y -35.7%
600867.SS
600867.SS • China
TONGHUA DONGBAO MEDICINES CO LT
7.88 CNY
2.31B USD 1Y -7%
600535.SS
600535.SS • China
TASLY PHARMACEUTICAL GROUP CO L
14.2 CNY
3.17B USD 1Y -10.3%
603456.SS
603456.SS • China
ZHEJIANG JIUZHOU PHARMACEUTICAL
16.31 CNY
2.14B USD 1Y -20.9%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%
600062.SS
600062.SS • China
CHINA RESOURCES DOUBLE-CRANE PH
16.44 CNY
2.55B USD 1Y -13.1%
605507.SS
605507.SS • China
GUOBANG PHARMA LTD
17.31 CNY
2.03B USD 1Y +7.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
28.4% p.a.
Max Drawdown (5Y)
-34.2%
Sharpe Ratio (5Y)
-0.20
Beta Factor
0.11
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -57.8% in the extended horizon.
ende